JAK2 and essential thrombocythemia: Overall, this study supports the pathogenetic model in which JAK2V617F-positive ET and PV could be considered as different phenotypes or phases of a single MPN characterized by JAK2 mutation47, whereas CALR-mutated ET seems to be a distinct entity both at clinical13 and at molecular level.